FTC crashes tea party
This article was originally published in The Tan Sheet
The Federal Trade Commission orders $31.7 million judgement against health care companies for marketing an herbal tea with unsubstantiated claims and deceptively selling health care business opportunities. The defendants claimed an herbal tea they sold could prevent, treat or cure diseases including AIDS, diabetes, cancer and arthritis, FTC says. The defendants - Jeffrey W. McLain, his sons Alexander McLain and Victor McLain, and the firms Prophet 3H, Georgia Home Health Care License and Certification Institute, Healthcare State License and Certification Institute, and M7 Holdings - also conducted conferences to sell "bogus healthcare business ventures," FTC says Dec. 21...
You may also be interested in...
A lack of regulatory harmonization for dietary supplements in Asia is a big challenge facing companies operating in the region, according to experts from the Asia Regulatory Professionals Association. The ARPA is looking to start a conversation on the issue which the association hopes will lead to regulatory change.
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Company is confident that data readout from pivotal trial could be ready before the end of 2020.